DOI

10.1016/S0140-6736(13)61572-X

Type

Journal article

Journal

Lancet

Publication Date

03/08/2013

Volume

382

Pages

369 - 370

Keywords

Cost-Benefit Analysis, Drug Costs, Humans, Immunization Programs, Meningitis, Meningococcal, Meningococcal Vaccines, Neisseria meningitidis, Serogroup B, United Kingdom, Vaccination